Prescription Drugs Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	140 Pages	Fortune Business Insights Pvt. Ltd.	October, 2024	FOB19224264

Best Price Guarantee
Price	from $4,850
Length	140 Pages
Publisher	Fortune Business Insights Pvt. Ltd.
Published Date	October, 2024
SKU	FOB19224264

Prescription Drugs Market

Growth Factors of Prescription Drugs Market

The global prescription drugs market size was valued at USD 1162.61 billion in 2023 and is projected to grow from USD 1,240.33 billion in 2024 to USD 2,151.63 billion by 2032, exhibiting a CAGR of 7.1% during the forecast period of 2024-2032.

The COVID-19 pandemic disrupted supply chains and delayed scientific trials in the Prescription Drugs Market, main to shortages of raw substances. Conversely, it heightened the call for medicinal drugs associated with breathing situations, antivirals, and vaccines, even as increasing authorities' consciousness on healthcare contributed to the marketplace boom, impeding the prescription drugs market growth.

The Prescription Drugs Market is ordinarily driven by the growing prevalence of continual diseases, an aging populace, and heightened healthcare spending. Innovations in pharmaceutical studies, a focal point on personalized medicine, and a developing call for strong point tablets and biologics also contribute to market growth, supported through favorable regulatory frameworks.

As a sub-sector of prescription drugs, the rising of customization through genetic and other features of an individual patient is seen to be a new trend. Genetic testing prescribes populations that may require particular therapies or will be endangered by definite pathologies, broadening the prescription drugs share worldwide. These details are then used to choose the correct medication and treatment procedures. Moreover, such treatment strategies as molecular targeted therapy are being adopted for effective molecular targets of diseases that define more effective treatment plans.

Comprehensive Analysis of Prescription Drugs Market

The prescription drug market is segmented by product type, remedy, and distribution channel. In product types, other prescription drugs dominate due to rising prescriptions for continual situations, with orphan tablets expected to grow quicker due to accelerated scientific trials and approvals. The oncology remedy segment leads the marketplace, fueled by rising cancer prevalence and new-centered cures. Additionally, health center pharmacies are the number one distribution channel, providing vital therapeutics requiring professional management, while online pharmacies are anticipated to develop hastily because of their convenience.

The North America region led the prescription drugs market by benefitting a size of USD 576.35 billion in 2023 due to the high incidence of various continual illnesses in the area, the North America pharmaceuticals market has experienced dominance.

The leading prescription drug market players significantly shape its growth trajectory and establish industry standards. Key companies such as Novartis AG (Switzerland), Pfizer, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Sanofi (France), Johnson & Johnson Services, Inc. (U.S.), Merck & Co., Inc. (U.S.), AbbVie, Inc. (U.S.), GlaxoSmithKline plc (U.K.), AstraZeneca (U.K.), and CELGENE CORPORATION (BRISTOL-MYERS SQUIBB COMPANY) (U.S.) contribute to a competitive landscape, driving innovation and advancements in the market.

In October 2023, Novartis AG identified that strategies to demerge Sandoz, generics, and biosimilar divisions enabled you to move to an organization based on new-age medicine.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 7.1% from 2024-2032

Unit Value (USD billion)

Segmentation By Product Type

Generics
Orphan
Other Prescription Drugs

By Application

Oncology
Central Nervous System
Vaccines
Immunosuppressants
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies & Drug Stores
Others

By Geography

North America (By Product Type, By Application, By Distribution Channel, and By Country)
U.S.
Canada
Europe (By Product Type, By Diabetes Type, By Distribution Channel, and By Country/Sub-region)
U.K.
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region)
China
Japan
India
Australia
Southeast Asia
Rest of Asia Pacific
Latin America (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region)
Brazil
Mexico
Rest of Latin America
Middle East & Africa (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region)
GCC
South Africa
Rest of Middle East & Africa

Please Note: It will take 5-6 business days to complete the report upon order confirmation.

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology; 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities; 3.4. Market Trends
4. Key Insights: 4.1. Prevalence of Key Diseases - By Key Countries/ Region, 2023; 4.2. Pipeline Analysis, By Key Players; 4.3. Key Industry Developments, By Key Players; 4.4. Regulatory Scenario, By Key Regions; 4.5. New Product Launches, By Key Players; 4.6. Impact of COVID-19 on the Market
5. Global Prescription Drugs Market Analysis, Insights and Forecast, 2019-2032: 5.1. Market Analysis, Insights and Forecast – By Product Type; 5.1.1. Generics; 5.1.2. Orphan; 5.1.3. Other Prescription Drugs; 5.2. Market Analysis, Insights and Forecast – By Application; 5.2.1. Oncology; 5.2.2. Central Nervous System; 5.2.3. Vaccines; 5.2.4. Immunosuppressants; 5.2.5. Others; 5.3. Market Analysis, Insights and Forecast – By Distribution Channel; 5.3.1. Hospital Pharmacies; 5.3.2. Retail Pharmacies & Drug Stores; 5.3.3. Online Pharmacies; 5.4. Market Analysis, Insights and Forecast – By Region; 5.4.1. North America; 5.4.2. Europe; 5.4.3. Asia Pacific; 5.4.4. Latin America; 5.4.5. Middle East & Africa
6. North America Prescription Drugs Market Analysis, Insights and Forecast, 2019-2032: 6.1. Market Analysis, Insights and Forecast – By Product Type; 6.1.1. Generics; 6.1.2. Orphan; 6.1.3. Other Prescription Drugs; 6.2. Market Analysis, Insights and Forecast – By Application; 6.2.1. Oncology; 6.2.2. Central Nervous System; 6.2.3. Vaccines; 6.2.4. Immunosuppressants; 6.2.5. Others; 6.3. Market Analysis, Insights and Forecast – By Distribution Channel; 6.3.1. Hospital Pharmacies; 6.3.2. Retail Pharmacies & Drug Stores; 6.3.3. Online Pharmacies; 6.4. Market Analysis, Insights and Forecast – By Country; 6.4.1. U.S.; 6.4.2. Canada
7. Europe Prescription Drugs Market Analysis, Insights and Forecast, 2019-2032: 7.1. Market Analysis, Insights and Forecast – By Product Type; 7.1.1. Generics; 7.1.2. Orphan; 7.1.3. Other Prescription Drugs; 7.2. Market Analysis, Insights and Forecast – By Application; 7.2.1. Oncology; 7.2.2. Central Nervous System; 7.2.3. Vaccines; 7.2.4. Immunosuppressants; 7.2.5. Others; 7.3. Market Analysis, Insights and Forecast – By Distribution Channel; 7.3.1. Hospital Pharmacies; 7.3.2. Retail Pharmacies & Drug Stores; 7.3.3. Online Pharmacies; 7.4. Market Analysis, Insights and Forecast – By Country/ Sub-region; 7.4.1. U.K.; 7.4.2. Germany; 7.4.3. France; 7.4.4. Spain; 7.4.5. Italy; 7.4.6. Rest of Europe
8. Asia Pacific Prescription Drugs Market Analysis, Insights and Forecast, 2019-2032: 8.1. Market Analysis, Insights and Forecast – By Product Type; 8.1.1. Generics; 8.1.2. Orphan; 8.1.3. Other Prescription Drugs; 8.2. Market Analysis, Insights and Forecast – By Application; 8.2.1. Oncology; 8.2.2. Central Nervous System; 8.2.3. Vaccines; 8.2.4. Immunosuppressants; 8.2.5. Others; 8.3. Market Analysis, Insights and Forecast – By Distribution Channel; 8.3.1. Hospital Pharmacies; 8.3.2. Retail Pharmacies & Drug Stores; 8.3.3. Online Pharmacies; 8.4. Market Analysis, Insights and Forecast – By Country/ Sub-region; 8.4.1. Japan; 8.4.2. China; 8.4.3. India; 8.4.4. Australia; 8.4.5. Southeast Asia; 8.4.6. Rest of Asia Pacific
9. Latin America Prescription Drugs Market Analysis, Insights and Forecast, 2019-2032: 9.1. Market Analysis, Insights and Forecast – By Product Type; 9.1.1. Generics; 9.1.2. Orphan; 9.1.3. Other Prescription Drugs; 9.2. Market Analysis, Insights and Forecast – By Application; 9.2.1. Oncology; 9.2.2. Central Nervous System; 9.2.3. Vaccines; 9.2.4. Immunosuppressants; 9.2.5. Others; 9.3. Market Analysis, Insights and Forecast – By Distribution Channel; 9.3.1. Hospital Pharmacies; 9.3.2. Retail Pharmacies & Drug Stores; 9.3.3. Online Pharmacies; 9.4. Market Analysis, Insights and Forecast – By Country/ Sub-region; 9.4.1. Brazil; 9.4.2. Mexico; 9.4.3. Rest of Latin America
10. Middle East & Africa Prescription Drugs Market Analysis, Insights and Forecast, 2019-2032: 10.1. Market Analysis, Insights and Forecast – By Product Type; 10.1.1. Generics; 10.1.2. Orphan; 10.1.3. Other Prescription Drugs; 10.2. Market Analysis, Insights and Forecast – By Application; 10.2.1. Oncology; 10.2.2. Central Nervous System; 10.2.3. Vaccines; 10.2.4. Immunosuppressants; 10.2.5. Others; 10.3. Market Analysis, Insights and Forecast – By Distribution Channel; 10.3.1. Hospital Pharmacies; 10.3.2. Retail Pharmacies & Drug Stores; 10.3.3. Online Pharmacies; 10.4. Market Analysis, Insights and Forecast – By Country/ Sub-region; 10.4.1. GCC; 10.4.2. South Africa; 10.4.3. Rest of Middle East & Africa
11. Competitive Analysis: 11.1. Global Market Share Analysis (2023); 11.2. Company Profiles; 11.2.1. Novartis AG; 11.2.1.1. Overview; 11.2.1.2. Products & Services; 11.2.1.3. SWOT Analysis; 11.2.1.4. Recent Developments; 11.2.1.5. Strategies; 11.2.1.6. Financials (Based on Availability); 11.2.2. Pfizer, Inc.; 11.2.2.1. Overview; 11.2.2.2. Products & Services; 11.2.2.3. SWOT Analysis; 11.2.2.4. Recent Developments; 11.2.2.5. Strategies; 11.2.2.6. Financials (Based on Availability); 11.2.3. F. Hoffmann-La Roche Ltd.; 11.2.3.1. Overview; 11.2.3.2. Products & Services; 11.2.3.3. SWOT Analysis; 11.2.3.4. Recent Developments; 11.2.3.5. Strategies; 11.2.3.6. Financials (Based on Availability); 11.2.4. Sanofi; 11.2.4.1. Overview; 11.2.4.2. Products & Services; 11.2.4.3. SWOT Analysis; 11.2.4.4. Recent Developments; 11.2.4.5. Strategies; 11.2.4.6. Financials (Based on Availability); 11.2.5. Johnson & Johnson Services, Inc.; 11.2.5.1. Overview; 11.2.5.2. Products & Services; 11.2.5.3. SWOT Analysis; 11.2.5.4. Recent Developments; 11.2.5.5. Strategies; 11.2.5.6. Financials (Based on Availability); 11.2.6. Merck & Co., Inc.; 11.2.6.1. Overview; 11.2.6.2. Products & Services; 11.2.6.3. SWOT Analysis; 11.2.6.4. Recent Developments; 11.2.6.5. Strategies; 11.2.6.6. Financials (Based on Availability); 11.2.7. AbbVie, Inc.; 11.2.7.1. Overview; 11.2.7.2. Products & Services; 11.2.7.3. SWOT Analysis; 11.2.7.4. Recent Developments; 11.2.7.5. Strategies; 11.2.7.6. Financials (Based on Availability); 11.2.8. GlaxoSmithKline plc.; 11.2.8.1. Overview; 11.2.8.2. Products & Services; 11.2.8.3. SWOT Analysis; 11.2.8.4. Recent Developments; 11.2.8.5. Strategies; 11.2.8.6. Financials (Based on Availability); 11.2.9. AstraZeneca; 11.2.9.1. Overview; 11.2.9.2. Products & Services; 11.2.9.3. SWOT Analysis; 11.2.9.4. Recent Developments; 11.2.9.5. Strategies; 11.2.9.6. Financials (Based on Availability); 11.2.10. CELGENE CORPORATION (BRISTOL-MYERS SQUIBB COMPANY); 11.2.10.1. Overview; 11.2.10.2. Products & Services; 11.2.10.3. SWOT Analysis; 11.2.10.4. Recent Developments; 11.2.10.5. Strategies; 11.2.10.6. Financials (Based on Availability); 12.